COMMUNIQUÉS West-GlobeNewswire

Memo Therapeutics AG Presents Complete Phase II Clinical Trial Data for Potravitug in Kidney Transplant Recipients at the American Transplant Congress 2026
18/06/2026
Complete SAFE KIDNEY II data confirm sustained reduction in viral load and resolution of biopsy-proven BKPyV-associated nephropathy with continued antiviral effect to 38 weeks Systematic literature review demonstrates [...]
Hi*Ball Energy Arrives in the UK, Leading a New Wave of Clean Energy
18/06/2026
Refresh Your Energy with Hi*Ball Sparkling Energy Water, a bold new energy drink powered by natural caffeine and functional ingredients, with zero sugar, zero calories, and zero compromise. Hi*Ball Debuts at Barcode [...]
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
18/06/2026
BiTAC-ADC in vitro data, along with initial data from the most advanced BiTAC-TCE program recently presented at the American Association for Cancer Research (AACR) Annual Meeting, underpin the Company’s two viable and [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
18/06/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 18 June 2026 at 14.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
18/06/2026
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has [...]
Asimov Announces Strategic Partnership with the Rosalind & Morris Goodman Cancer Institute at McGill University to Advance Next-Generation Biologics
18/06/2026
Asimov will provide cell line development and process development services to support promising biotherapeutic molecules identified through McGill’s oncology research programs BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- [...]
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
18/06/2026
NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is [...]
Alturos Therapeutics advancement of lead candidate ALT0135, a potentially first-in-class, orally bioavailable small molecule, into IND-enabling studies
18/06/2026
www.alturostx.com Tilburg, the Netherlands – June 18, 2026 - Alturos Therapeutics B.V., , a biopharmaceutical company focused on developing transformative therapies for neurodegenerative diseases, today announced the [...]
De nouvelles données sur l’association TALVEY®▼ (talquetamab) et daratumumab démontrent le potentiel d’une nouvelle association bispécifique dans les lignes précoces du traitement du myélome multiple récidivant ou réfractaire
18/06/2026
L’association TALVEY ® et daratumumab, avec ou sans pomalidomide, a montré une survie sans progression pouvant atteindre 81,3 % et une survie globale pouvant atteindre 89,2 % à 24 mois 1 MonumenTAL-3 est la troisième [...]
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
18/06/2026
REYKJAVIK, Iceland, June 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar [...]
Zelluna ASA: Disclosure of large shareholding
18/06/2026
Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 18 June 2026 regarding the total allocation of 3,143,958 new shares in the Company in a private placement and a retail offering [...]
New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF
18/06/2026
Not intended for UK and US audiences Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026 international [...]
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
18/06/2026
REYKJAVIK, ICELAND (June 18, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients [...]
BIO-Europe unveils renewed vision as the must-attend global biopharma strategy forum
18/06/2026
2026 marks BIO-Europe's evolution from partnering-led conference into the continent's largest biopharma strategy forum Expands its program to convene the full C-suite of strategy leaders, building on its commitment to [...]
Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
18/06/2026
Press Release Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470 Exclusive licensee for China, Ocumension, received positive pre-submission regulatory feedback from [...]
Nicox annonce des retours réglementaires préalables positifs en Chine soutenant le dépôt du NDA pour NCX 470
18/06/2026
Communiqué de presse Nicox annonce des retours réglementaires préalables positifs en Chine soutenant le dépôt du NDA pour NCX 470 Ocumension, notre partenaire licencié exclusif pour la Chine, a reçu des retours [...]
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
18/06/2026
Filing acceptance based on data from the phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of disease progression or death 1 People with relapsed or refractory LBCL [...]
F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients With Invasive Aspergillosis
18/06/2026
The study achieved the primary endpoint of non-inferiority, with a rate of all-cause mortality (ACM) at Day 42 for olorofim of 23.8% and for AmBisome® followed by standard of care of 24.3% No new safety findings were [...]
Legend Biotech Corporation Announces Pricing of Public Offering
18/06/2026
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public [...]

Pages